Published in Expert Opin Pharmacother on February 21, 2013
Biologic therapy for refractory scleritis: a new treatment perspective. Int Ophthalmol (2015) 0.78
Flurbiprofen: A Nonselective Cyclooxygenase (COX) Inhibitor for Treatment of Noninfectious, Non-necrotizing Anterior Scleritis. Ocul Immunol Inflamm (2015) 0.75
Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 11.05
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med (1983) 8.26
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med (2005) 6.37
Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol (2000) 4.70
A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum (1997) 3.62
Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med (1991) 2.77
Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther (2002) 2.58
Microbial scleritis-experience from a developing country. Eye (Lond) (2008) 2.24
Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ (2009) 2.23
Surgically induced necrotising sclerokeratitis (SINS)--precipitating factors and response to treatment. Br J Ophthalmol (1992) 2.22
Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology (2007) 2.17
Cicatricial pemphigoid. Trans Am Ophthalmol Soc (1986) 2.10
Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology (1999) 2.02
Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet (1989) 1.92
Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum (2001) 1.85
Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology (2011) 1.85
Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol (2005) 1.81
Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2007) 1.78
Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum (1995) 1.78
Cyclosporine for ocular inflammatory diseases. Ophthalmology (2010) 1.75
Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.74
The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg (1996) 1.71
Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol (2000) 1.70
Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol (2009) 1.69
Clinical experiences of infectious scleral ulceration: a complication of pterygium operation. Br J Ophthalmol (1997) 1.68
Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2010) 1.66
Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol (2009) 1.62
Long-term, multicenter evaluation of subconjunctival injection of triamcinolone for non-necrotizing, noninfectious anterior scleritis. Ophthalmology (2011) 1.60
Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum (2009) 1.59
Methotrexate for ocular inflammatory diseases. Ophthalmology (2009) 1.58
An analysis of therapeutic decision for scleritis. Ophthalmology (1993) 1.55
Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology (2008) 1.46
Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology (2005) 1.46
Recombinant human tumor necrosis factor receptor Fc fusion protein (Etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration. Eye Contact Lens (2004) 1.46
HIV-seropositive patient with Sweet's syndrome and nodular scleritis, showing dramatic response after adding dapsone to systemic corticosteroid therapy. Int J Dermatol (2008) 1.44
Azathioprine for ocular inflammatory diseases. Am J Ophthalmol (2009) 1.44
Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol (2009) 1.41
Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease. Am J Med (1984) 1.37
T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol (2012) 1.24
Therapy insight: scleritis and its relationship to systemic autoimmune disease. Nat Clin Pract Rheumatol (2007) 1.24
Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) (2008) 1.20
Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm (2012) 1.19
Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology (2004) 1.16
Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs (2009) 1.16
Epidemiology and visual outcomes in patients with infectious scleritis. Cornea (2013) 1.15
Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis (2008) 1.15
Cyclophosphamide for ocular inflammatory diseases. Ophthalmology (2009) 1.14
Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol (2000) 1.13
Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol (2006) 1.13
Intravenous pulse methylprednisolone in scleritis. Arch Ophthalmol (1987) 1.12
Infectious scleritis after retinal surgery. Am J Ophthalmol (2008) 1.12
Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis (2005) 1.10
Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond) (2006) 1.07
Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol (2005) 1.07
Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H. Br J Ophthalmol (1995) 1.06
Successful treatment of surgically induced necrotizing scleritis with tacrolimus. Clin Experiment Ophthalmol (2005) 1.04
Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol (2007) 1.03
Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med (2003) 1.03
Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol (2010) 1.01
Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology (2008) 1.01
Infliximab for the treatment of refractory scleritis. Br J Ophthalmol (2009) 1.01
Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol (2012) 1.01
Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm (2011) 1.01
Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis (2010) 1.00
Infliximab for the treatment of active scleritis. Can J Ophthalmol (2009) 1.00
Azathioprine and severe bone marrow depression. Lancet (1986) 0.99
Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med (1984) 0.98
Subconjunctival corticosteroid injection for the treatment of non-necrotising anterior scleritis. Br J Ophthalmol (2005) 0.97
Treatment of Behcet disease with chlorambucil. A follow-up report. Arch Ophthalmol (1976) 0.96
Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology (2003) 0.96
Immunosuppressive agents: recent developments in molecular action and clinical application. Transplant Proc (1998) 0.95
Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med (2000) 0.95
Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol (2012) 0.94
The diagnosis and management of scleritis. Ophthalmology (1980) 0.93
Evaluation of subconjunctival triamcinolone for nonnecrotizing anterior scleritis. Ophthalmology (2005) 0.93
Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology (2010) 0.93
Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) (2003) 0.92
Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol (2002) 0.92
Golimumab for uveitis. Ophthalmology (2011) 0.92
Retrospective review of methotrexate therapy in the treatment of chronic, noninfectious, nonnecrotizing scleritis. Am J Ophthalmol (2008) 0.91
Treatment of orbital myositis with adalimumab (Humira). J Rheumatol (2005) 0.91
An update on the cause and treatment of scleritis. Curr Opin Ophthalmol (2010) 0.91
Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol (2010) 0.90
Immunologic markers as potential predictors of systemic autoimmune disease in patients with idiopathic scleritis. Am J Ophthalmol (2007) 0.89
Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol (2007) 0.89
Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology (2002) 0.89
Early surgical debridement in the management of infectious scleritis after pterygium excision. J Ophthalmic Inflamm Infect (2012) 0.89
Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev (2011) 0.88
Successful treatment of refractory sympathetic ophthalmia in a child with infliximab. Arch Ophthalmol (2011) 0.88
Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology (2002) 0.88
Immunosuppressive drugs in the management of progressive, corticosteroid-resistant uveitis associated with juvenile rheumatoid arthritis. Int Ophthalmol Clin (1992) 0.88
Nodular scleritis and Sweet's syndrome. Clin Experiment Ophthalmol (2007) 0.88
Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm (2006) 0.88
Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report. J Rheumatol (2008) 0.87
The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol (2000) 0.87
Relapsing polychondritis: systemic and ocular manifestations, differential diagnosis, management, and prognosis. Semin Ophthalmol (2011) 0.87
Dapsone-induced hemolytic anemia in lung allograft recipients. J Heart Lung Transplant (2008) 0.86
Scleritis in relapsing polychondritis. Response to therapy. Ophthalmology (1990) 0.86
Topical cyclosporine for treating necrotizing scleritis. Arch Ophthalmol (1995) 0.85
Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol (2005) 13.50
A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol (2005) 3.50
Childhood uveitis-young patients, old problems, new perspectives. J AAPOS (2008) 3.12
Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum (2007) 3.11
Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ (2009) 2.23
NOD2 transgenic mice exhibit enhanced MDP-mediated down-regulation of TLR2 responses and resistance to colitis induction. Gastroenterology (2007) 2.03
Uveitis in patients with autoimmune hepatitis. Am J Ophthalmol (2009) 2.02
Epidemiologic relationship between fuchs heterochromic iridocyclitis and the United States rubella vaccination program. Am J Ophthalmol (2007) 1.89
Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol (2008) 1.87
The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis Rheum (2009) 1.87
Identification of a susceptibility locus in STAT4 for Behçet's disease in Han Chinese in a genome-wide association study. Arthritis Rheum (2012) 1.84
Cyclosporine for ocular inflammatory diseases. Ophthalmology (2010) 1.75
Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol (2009) 1.69
Preclinical evaluation and intraoperative human retinal imaging with a high-resolution microscope-integrated spectral domain optical coherence tomography device. Retina (2013) 1.68
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun (2003) 1.66
Gene expression profiling of whole blood: comparison of target preparation methods for accurate and reproducible microarray analysis. BMC Genomics (2009) 1.64
Adverse effects of smoking on patients with ocular inflammation. Br J Ophthalmol (2010) 1.61
Methotrexate for ocular inflammatory diseases. Ophthalmology (2009) 1.58
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm (2007) 1.53
Azathioprine for ocular inflammatory diseases. Am J Ophthalmol (2009) 1.44
Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology (2002) 1.42
Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol (2009) 1.41
Epidemiology and course of disease in childhood uveitis. Ophthalmology (2009) 1.35
Unique gene expression profiles of donor-matched human retinal and choroidal vascular endothelial cells. Invest Ophthalmol Vis Sci (2007) 1.32
Pediatric granulomatous arthritis: an international registry. Arthritis Rheum (2006) 1.31
Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood (2002) 1.30
Enhanced recognition, treatment, and prognosis of tubulointerstitial nephritis and uveitis syndrome. Ophthalmology (2007) 1.28
Antineutrophil cytoplasmic antibody-associated active scleritis. Arch Ophthalmol (2008) 1.28
Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest. Am J Ophthalmol (2008) 1.26
Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis. J Rheumatol (2005) 1.25
Therapy insight: scleritis and its relationship to systemic autoimmune disease. Nat Clin Pract Rheumatol (2007) 1.24
Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol (2008) 1.23
Constitutive and inflammatory mediator-regulated fractalkine expression in human ocular tissues and cultured cells. Invest Ophthalmol Vis Sci (2003) 1.21
Interferon alpha 2b in the treatment of uveitic cystoid macular edema. Ocul Immunol Inflamm (2012) 1.16
Cyclophosphamide for ocular inflammatory diseases. Ophthalmology (2009) 1.14
Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol (2006) 1.13
Does the microbiome play a causal role in spondyloarthritis? Clin Rheumatol (2014) 1.12
Management of uveitis: a rheumatologic perspective. Arthritis Rheum (2002) 1.11
Epifluorescence intravital microscopy of murine corneal dendritic cells. Invest Ophthalmol Vis Sci (2009) 1.09
Strong associations between specific HLA-DQ and HLA-DR alleles and the tubulointerstitial nephritis and uveitis syndrome. Invest Ophthalmol Vis Sci (2003) 1.08
NOD2, the gene responsible for familial granulomatous uveitis, in a mouse model of uveitis. Invest Ophthalmol Vis Sci (2008) 1.08
Interleukin-17 causes neutrophil mediated inflammation in ovalbumin-induced uveitis in DO11.10 mice. Cytokine (2009) 1.08
Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy. Invest Ophthalmol Vis Sci (2005) 1.07
Insights in to the pathogenesis of axial spondyloarthropathy based on gene expression profiles. Arthritis Res Ther (2009) 1.07
Antigen-specific accumulation of naïve, memory and effector CD4 T cells during anterior uveitis monitored by intravital microscopy. Cell Immunol (2006) 1.04
Risk of hypotony in noninfectious uveitis. Ophthalmology (2012) 1.03
Genetic studies in familial ankylosing spondylitis susceptibility. Arthritis Rheum (2004) 1.03
In vivo confocal microscopy of keratic precipitates. Arch Ophthalmol (2004) 1.03
APCs in the anterior uveal tract do not migrate to draining lymph nodes. J Immunol (2004) 1.03
A standardized grading system for scleritis. Ophthalmology (2010) 1.03
Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis. Arthritis Rheumatol (2015) 1.02
Proteomic profiling of human retinal and choroidal endothelial cells reveals molecular heterogeneity related to tissue of origin. Mol Vis (2007) 1.02
Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol (2013) 1.02
Toll-like receptor 4 and CD14 expression in human ciliary body and TLR-4 in human iris endothelial cells. Exp Eye Res (2004) 1.01
NOD1 expression in the eye and functional contribution to IL-1beta-dependent ocular inflammation in mice. Invest Ophthalmol Vis Sci (2008) 1.01
NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain. Arthritis Rheum (2009) 1.01
A locus on chromosome 9p predisposes to a specific disease manifestation, acute anterior uveitis, in ankylosing spondylitis, a genetically complex, multisystem, inflammatory disease. Arthritis Rheum (2005) 1.00
Hypopyon in patients with uveitis. Ophthalmology (2009) 0.99
Immunohistology of antigen-presenting cells in vivo: a novel method for serial observation of fluorescently labeled cells. Invest Ophthalmol Vis Sci (2003) 0.99
Hemin exerts multiple protective mechanisms and attenuates dextran sulfate sodium-induced colitis. J Pediatr Gastroenterol Nutr (2010) 0.98
Nucleotide-binding oligomerization domain 2 and Toll-like receptor 2 function independently in a murine model of arthritis triggered by intraarticular peptidoglycan. Arthritis Rheum (2010) 0.98
Interplay between innate and adaptive immunity in the development of non-infectious uveitis. Prog Retin Eye Res (2011) 0.98
Nucleotide oligomerization domain-2 interacts with 2'-5'-oligoadenylate synthetase type 2 and enhances RNase-L function in THP-1 cells. Mol Immunol (2009) 0.98
Human endothelial cells express NOD2/CARD15 and increase IL-6 secretion in response to muramyl dipeptide. Microvasc Res (2006) 0.98
Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology (2012) 0.97
Investigation of the differential potentials of TLR agonists to elicit uveitis in mice. J Leukoc Biol (2011) 0.97
Orbital inflammatory disease. Semin Arthritis Rheum (2007) 0.97
Ocular disease in patients with ANCA-positive vasculitis. J Ocul Biol Dis Infor (2009) 0.95
Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol (2002) 0.95
An update on the genetics of HLA B27-associated acute anterior uveitis. Ocul Immunol Inflamm (2011) 0.94
HLA-B27-associated uveitis: overview and current perspectives. Curr Opin Ophthalmol (2003) 0.93
Neutralization of IL-17 ameliorates uveitis but damages photoreceptors in a murine model of spondyloarthritis. Arthritis Res Ther (2012) 0.93
Differential expression of microRNA and predicted targets in pulmonary sarcoidosis. Biochem Biophys Res Commun (2011) 0.93
Characterizing extravascular neutrophil migration in vivo in the iris. Inflammation (2008) 0.93
Beta 3-adrenergic receptors mediate choroidal endothelial cell invasion, proliferation, and cell elongation. Exp Eye Res (2005) 0.93
Nucleotide oligomerization domain-2 (NOD2)-induced uveitis: dependence on IFN-gamma. Invest Ophthalmol Vis Sci (2008) 0.92
Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol (2007) 0.92
Homocysteine upregulates vascular cell adhesion molecule-1 expression in cultured human aortic endothelial cells and enhances monocyte adhesion. Arterioscler Thromb Vasc Biol (2002) 0.91
Mycophenolate mofetil for the treatment of scleritis. Ophthalmology (2003) 0.91
The intestinal microbiome in spondyloarthritis. Curr Opin Rheumatol (2015) 0.90
Response of pediatric uveitis to tumor necrosis factor-α inhibitors. J Rheumatol (2013) 0.90